Loading...
•
Sep 30, 2024
Arbutus Q3 2024 Earnings Report
Arbutus reported third quarter financial results and provided a corporate update.
Key Takeaways
Arbutus Biopharma reported a net loss of $19.7 million for the third quarter of 2024, with total revenue of $1.3 million. The company's cash runway extends into the fourth quarter of 2026, and it is advancing the development of imdusiran and AB-101.
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024.
Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy.
Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial.
Cash runway into the fourth quarter of 2026.
Arbutus
Arbutus
Arbutus Revenue by Segment
Revenue by Segment
Collaborations & Licenses Revenue
CapyFin.comNon-cash Royalty Revenue
CapyFin.com Forward Guidance
Arbutus expects its 2024 cash burn to range from $63 million to $67 million and believes its cash, cash equivalents and investments in marketable securities will be sufficient to fund its operations into the fourth quarter of 2026.
Revenue & Expenses
Visualization of income flow from segment revenue to net income